20.12亿美元!默沙东引进翰森制药一款临床前小分子GLP-1激动剂

Medaverse
18 Dec 2024

12月18日,翰森制药宣布公司全资附属公司上海翰森生物医药科技有限公司及江苏豪森药业集团有限公司(统称许可人)与Merck Sharp & Dohme LLC(默沙东)的一全资附属公司(被许可人)订立全球独家许可协议(许可协议)。根据许可协议,翰森制将授予默沙东开发、生产及商业化临床前口服小分子GLP-1受主激动剂HS-10535(该产品)的全球独家许可。翰森制将获得1.12亿美元首付款,并有资格...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10